Business
Altimmune to Participate at Leerink Partners Therapeutics Forum
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Vipin GargPresident and Chief Executive OfficerPhone: [email protected] Investor Contacts:Lee RothBurns McClellanPhone: [email protected] Julia WeilmanBurns McClellanPhone: [email protected] Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: [email protected] \nSource: Altimmune, Inc","length":5326,"tagName":"div"}]